What Does Forma Therapeutics Do?

Total employees200
HeadquartersWatertown
Founded2007

Forma Therapeutics was a clinical-stage biopharmaceutical company dedicated to the research, development, and commercialization of transformative medicines for patients with rare hematologic diseases and cancers. Its primary focus was on sickle cell disease (SCD), with its lead candidate etavopivat, and other rare blood disorders. In October 2022, Forma Therapeutics was acquired by Novo Nordisk, integrating its innovative pipeline and expertise into Novo Nordisk's broader rare disease portfolio to accelerate therapeutic advancements for patients.

Where Is Forma Therapeutics's Headquarters?

HQ Function

The Watertown headquarters served as the central nexus for Forma's research and development activities, clinical trial operations, and corporate administration, spearheading the company's mission to create treatments for rare hematologic conditions and cancers.

Notable Features:

Located in 'The Arsenal on the Charles,' a redeveloped historic arsenal complex, the facility featured modern laboratory spaces tailored for drug discovery and research, alongside collaborative office environments designed to foster innovation and teamwork.

Work Culture:

As a clinical-stage biopharmaceutical entity, Forma Therapeutics cultivated a dynamic, science-centric, and patient-oriented work culture. This environment emphasized intensive collaboration, pioneering innovation, and a steadfast commitment to addressing unmet medical needs in rare diseases, typical of a fast-paced drug development setting.

HQ Significance:

The Watertown location was strategically important due to its immersion in the Greater Boston area, a globally recognized cluster of leading academic institutions, cutting-edge research organizations, and numerous biotech and pharmaceutical companies. This proximity facilitated talent acquisition, scientific collaboration, and industry partnerships.

Values Reflected in HQ: The selection of a modernized, repurposed facility within a premier biotech ecosystem like Greater Boston underscored Forma's core values of innovation, scientific excellence, collaboration, and a forward-thinking commitment to developing life-changing medicines.

Location:

Prior to its acquisition by Novo Nordisk, Forma Therapeutics' global footprint was primarily characterized by its international clinical trial operations and strategic collaborations. While its physical R&D and corporate offices were U.S.-based in Watertown, MA, the company managed and conducted clinical studies for its drug candidates, such as etavopivat for sickle cell disease, across multiple countries. This involved extensive engagement with clinical research organizations (CROs), medical investigators, and patient advocacy groups worldwide to advance its therapeutic programs. Additionally, its business development and scientific outreach activities involved interactions with potential partners, academic institutions, and stakeholders on a global scale.

Street Address:

500 Arsenal Street, Suite 100

City:

Watertown

State/Province:

MA

Country:

USA

Where Else Does Forma Therapeutics Operate Around the World?

Watertown, MA, USA (Primary Location)

Address: Operations were largely centralized at the 500 Arsenal Street, Watertown, MA headquarters. Historically, Forma had other research sites (e.g., Branford, CT), but these were consolidated over time to enhance focus and collaboration at the main facility leading up to its acquisition by Novo Nordisk.

To streamline operations and foster a cohesive R&D and corporate environment within the strategic Greater Boston biotech ecosystem, ensuring focused efforts on its therapeutic pipeline.

Buying Intent Signals for Forma Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Forma Therapeutics? Meet the Executive Team

As of April 2025, Forma Therapeutics' leadership includes:

Frank D. Lee - Former President and Chief Executive Officer
Line N. Kong - Former Chief Financial Officer
David N. Cook, Ph.D. - Former Chief Scientific Officer
Patrick Kelly, M.D. - Former Chief Medical Officer
Ruth Salman - Former Chief Human Resources Officer

Who's Investing in Forma Therapeutics?

Forma Therapeutics has been backed by several prominent investors over the years, including:

New Enterprise Associates (NEA)
RA Capital Management
Lilly Ventures
Biogen
The Baupost Group
Cormorant Asset Management
Novartis Institutes for BioMedical Research (early investor/partner)
Picardie Capital
Andera Partners (formerly Edmond de Rothschild Investment Partners)
Various PIPE investors associated with its public offering

What Leadership Changes Has Forma Therapeutics Seen Recently?

Hire1
Exits2

In the period leading up to its acquisition by Novo Nordisk in late 2022, Forma Therapeutics experienced notable executive transitions, particularly within its finance leadership. Following the completion of the acquisition, the existing executive team structure of Forma Therapeutics was integrated into Novo Nordisk's organization or individuals transitioned out of their roles as the company became part of Novo Nordisk.

Departures

Todd Shegog, Todd Shegog departed from his role as Chief Financial Officer.
Iftekhar Ahmed, Iftekhar Ahmed announced his planned departure as Chief Business Officer.

New Appointments:

Line N. Kong, Line N. Kong was appointed as Chief Financial Officer, previously serving as interim CFO.

What Technology (Tech Stack) Is Used byForma Therapeutics?

Discover the tools Forma Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Forma Therapeutics Email Formats and Examples

Prior to its acquisition by Novo Nordisk, Forma Therapeutics likely utilized common corporate email address formats based on employee names and its domain `formatherapeutics.com`. Standard patterns for biopharmaceutical companies include combinations of first name, last name, and initials. Post-acquisition, official communications would transition to Novo Nordisk's email systems, and the `formatherapeutics.com` domain may no longer be active for email correspondence.

Commonly, formats like `[first_initial][last]@formatherapeutics.com` (e.g., jsmith@formatherapeutics.com) or `[first].[last]@formatherapeutics.com` (e.g., john.smith@formatherapeutics.com) were probable. Example: flast@formatherapeutics.com

Format

jsmith@formatherapeutics.com

Example

70 (Historically; domain likely inactive or communications redirected post-acquisition)%

Success rate

What's the Latest News About Forma Therapeutics?

Novo NordiskOctober 17, 2022

Novo Nordisk completes acquisition of Forma Therapeutics

Novo Nordisk announced the successful completion of its acquisition of Forma Therapeutics, Holdings Inc. (Forma). The acquisition, including its lead development candidate etavopivat for sickle cell disease (SCD), aligns with Novo Nordisk’s strategy to enhance its presence in SCD and rare blood disorders....more

Business WireSeptember 1, 2022

Novo Nordisk to Acquire Forma Therapeutics for USD 1.1 Billion to Accelerate Development of Transformative Sickle Cell Disease Treatment

Novo Nordisk and Forma Therapeutics announced a definitive agreement for Novo Nordisk to acquire Forma Therapeutics for $20 per share in cash, representing a total equity value of $1.1 billion. The transaction aimed to leverage Novo Nordisk's expertise to advance Forma's SCD program....more

Business WireJune 12, 2022

Forma Therapeutics Presented Updated Data from Phase 1 Trial of Etavopivat in Sickle Cell Disease at EHA2022

Forma Therapeutics shared updated results from its Phase 1 clinical trial of etavopivat in patients with sickle cell disease (SCD) at the European Hematology Association (EHA) 2022 Congress. The data indicated etavopivat was generally well tolerated and showed positive effects on anemia and red blood cell health markers....more

GlobeNewswireJune 19, 2020

Forma Therapeutics Announced Pricing of Initial Public Offering

Forma Therapeutics announced the pricing of its initial public offering (IPO) of 13,882,352 shares of common stock at $17.00 per share, for gross proceeds of approximately $236.0 million. The company's shares began trading on the Nasdaq Global Select Market under the ticker 'FMTX'....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Forma Therapeutics, are just a search away.